Skip to main content
Clinical trial efficacy data
Navbar Image
Clinical trial efficacy data
This site is intended only for US healthcare professionals.

Clinical trial efficacy data

COSELA may reduce the rate of hospitalization due to chemotherapy-induced myelosuppression or sepsis5

  • The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia
a
Caution should be taken when interpreting data from the pooled analysis, owing to differences in the patient populations and chemotherapy backbones across the three studies.5
b
P=0.0088.5